Fluoxetine updated on 07-01-2025

Ear, face and neck anomalies

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S7349
R21461		 Wemakor, 2015 Ear, face and neck 1st trimester case control unexposed (general population or NOS) Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 0.85 [0.12;6.25] C 1/28   745/17,801 746 28
ref
S5882
R14702		 Ban (Controls unexposed, disease free), 2014 Ear, face, and neck malformations 1st trimester retrospective cohort (claims database) unexposed, disease free Adjustment: No Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 0.61 [0.04;9.85] C 0/3,189   83/325,294 83 3,189
ref
S7194
R20421		 Colvin, 2011 Congenital anomalies of ear, face, and neck 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 4.39 [1.40;13.79] -/291   224/94,561 - 291
ref
Total 3 studies 1.93 [0.53;7.07] 829 3,508
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Wemakor, 2015Wemakor, 2015 0.85[0.12; 6.25]7462829%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Ban (Controls unexposed, disease free), 2014Ban, 2014 1 0.61[0.04; 9.85]833,18918%ROB confusion: seriousROB selection: moderateROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Colvin, 2011Colvin, 2011 4.39[1.40; 13.79]-29153%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Total (3 studies) I2 = 34% 1.93[0.53; 7.07]8293,5080.210.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, disease free;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.50[0.44; 14.33]833,48040%NABan (Controls unexposed, disease free), 2014 Colvin, 2011 2 case control studiescase control studies 0.85[0.12; 6.25]74628 -NAWemakor, 2015 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.93[0.53; 7.07]8293,50834%NAWemakor, 2015 Ban (Controls unexposed, disease free), 2014 Colvin, 2011 3 Tags Adjustment   - No  - No 1.93[0.53; 7.07]8293,50834%NAWemakor, 2015 Ban (Controls unexposed, disease free), 2014 Colvin, 2011 3 Monotherapy   - substance alone among all Antidep ( ...  - substance alone among all Antidep (SSRI, SNRI, ...) 0.85[0.12; 6.25]74628 -NAWemakor, 2015 1   - substance alone among the specific ...  - substance alone among the specific class of antidep (SSRI, SNRI, ...) 2.50[0.44; 14.33]833,48040%NABan (Controls unexposed, disease free), 2014 Colvin, 2011 2 All studiesAll studies 1.93[0.53; 7.07]8293,50834%NAWemakor, 2015 Ban (Controls unexposed, disease free), 2014 Colvin, 2011 30.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.93[0.53; 7.07]1,0443,50834%NAWemakor, 2015 Ban (Controls unexposed, disease free), 2014 Colvin, 2011 30.510.01.0